Search our news archive and pharma companies…
|
Today's News | Note: News feeds may no longer be available for the articles on this page.
Genzyme
halts development on kidney treatment 9:20 AM 11/18/2009
Boston Globe
Genzyme Corp will not pursue further clinical development of its advanced
phosphate binder APB for kidney disease. APB was not better than Renvela.
...
Vivus
Drug For Erectile Dysfunction Meets Goals; Things Up 8:40 AM 11/18/2009
Wall Street Journal
Vivus Inc's drug candidate to treat erectile dysfunction
was found safe and effective in a late stage trial.
...
Biotech
Cosmo aims to buy rival BioXell for $41 mln 5:10 AM 11/18/2009
Reuters
Cosmo Pharmaceuticals plans to buy rival BioXell aiming to boost its portfolio of
experimental drug candidates. BioXell does not have a drug on the market and cut jobs after a clinical failure.
...
Poniard
rebounds on picoplatin colon cancer data 1:37 PM 11/17/2009
The Associated Press
Poniard Pharmaceuticals' drug candidate picoplatin failed to improve
survival for patients with lung cancer, but the company reported positive data on the drug as a treatment for
colorectal cancer.
...
Oxigene
drug meets safety goals in study 12:47 PM 11/17/2009
The Associated Press
Oxigene Inc said its lung cancer candidate Zybrestat met safety goals in
a midstage study.
...
FDA warns heartburn drugs interfere with Plavix 10:57 AM 11/17/2009
Reuters
New data show AstraZeneca's Prilosec (omeprazole) reduces the
anti-clotting effect of Plavix by almost half.
...
InterMune to modify
hep C study to drop one dosage 9:55 AM 11/17/2009
Reuters
InterMune Inc said it would discontinue one dosage in a mid-stage study testing its
experimental therapy to treat hepatitis C.
...
Isis
cholesterol drug meets all goals of key trial 9:15 AM 11/17/2009
Reuters
Isis Pharmaceuticals Inc and Genzyme Corp's experimental drug
for patients genetically disposed to extremely high cholesterol significantly lowered it in a pivotal late-stage
study, according to data presented on Tuesday.
The drug, mipomersen, attained the main goal of the trial, cutting "bad" LDL cholesterol by 25 percent, compared
with just a 3 percent reduction from placebo in patients with a very rare condition known as homozygous familial
hypercholesterolemia.
...
US
FDA staff question Pfizer lung drug data 9:05 AM 11/17/2009
Reuters
The companies are asking
the Food and Drug Administration for permission to claim the
blockbuster drug Spiriva reduces flare-ups of chronic obstructive
...
Discovery Labs submits lung drug
trial proposal to
FDA 8:18 AM 11/17/2009
Reuters
Discovery Laboratories Inc submitted a proposed protocol to the US FDA to conduct a limited clinical trial of its Surfaxin to treat respiratory illness in infants.
...
Novartis
says lower H1N1 vaccine dose may suffice 5:02 AM 11/17/2009
Reuters
A clinical study of 4,000 individuals suggests that just half a dose of
the Novartis' H1N1 vaccine may be enough to generate a protective immune response.
...
Nabi
makes deal for smoking vaccine 4:32 AM 11/17/2009
Washington Post
Nabi Bioparmaceuticals outlined the terms of a deal where GlaxoSmithKline has
agreed to pay $40 million initially for the exclusive worldwide licensing rights to the drug NicVax.
...
Genzyme says FDA declines
to approve Pompe disease
drug 5:14 PM 11/16/2009
Reuters
Genzyme Corp
is struggling through the most trying period in its history. The US FDA will not approve its drug to treat
Pompe disease until it addresses manufacturing deficiencies at its Allston Landing plant.
...
US FDA wants panel to
probe Pfizer vaccine
efficacy 4:13 PM 11/16/2009
Reuters
Pfizer Inc's next-generation Prevnar vaccine missed some of the main goals in a study
testing its ability to protect against bacteria that cause ear infections, pneumonia, and other diseases.
...
Alkermes says drug meets
main goal of late-stage
trial 8:34 AM 11/16/2009
Reuters
Alkermes Inc said its alcohol dependence drug Vivitrol (XR-NTX) met the main goal of a
late-stage study of opioid dependence.
...
<- Day Earlier | Today's News
|
